Aluda is on the move into the clinic with a revolutionary new treatment for Crohn's: the first mechanism that can address and enroll patients with complications from fibtmrotic strictures to refractory hyperinflammation to NOD2 Gene.
Thank you #CaLifeSciences and their #FASTadvisory program for selecting Aluda to present in the start up stadium at #BIO2024. thanks to the judges and full room to hearing a revolutionary approach to Severe Immune and Fibrotic disease through vimentin and its dramatic data in severe refactory #Crohns. Real help for severe patients is around the corner. #fibrosis #Tregs #regulatoryTcells #antifibrotic #nlrp3 #nod2 #TheMissingLinkisVimentin #Oxford #Kennedyinstitute Michael Dustin Ewoud Compeer